Wet Age-Related Macular Degeneration (Wet-AMD)- Pipeline Insight, 2025

DelveInsight’s, “Wet Age-Related Macular Degeneration (Wet-AMD)- Pipeline Insight, 2025” report provides comprehensive insights about 60+ companies and 70+ pipeline drugs in Wet Age-Related Macular Degeneration (Wet-AMD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Wet Age-Related Macular Degeneration (Wet-AMD): Understanding

Wet Age-Related Macular Degeneration (Wet-AMD): Overview

Wet Age-related Macular Degeneration (AMD) is a chronic eye disease that affects the macula, the central part of the retina responsible for sharp, detailed vision. It is a more severe form of AMD compared to the dry type and progresses rapidly, leading to significant vision loss if untreated. Wet AMD occurs when abnormal blood vessels grow under the macula, leaking blood or fluid, which disrupts retinal function and causes scarring. This condition primarily affects older adults, usually over the age of 50, and is a leading cause of central vision loss in this age group.

Wet AMD typically begins with blurred or distorted central vision, making it difficult to read, recognize faces, or perform tasks requiring precision. Straight lines may appear wavy (metamorphopsia), and dark or empty spots (scotomas) can develop in the central vision field. Symptoms often appear suddenly and worsen quickly. Peripheral vision is usually unaffected, allowing patients to retain some degree of sight.

Wet AMD arises from abnormal angiogenesis (blood vessel growth) under the retina, often triggered by the overproduction of vascular endothelial growth factor (VEGF). While the exact cause is unknown, risk factors include aging, genetics, smoking, obesity, high blood pressure, and a diet low in antioxidants. Environmental factors, such as prolonged exposure to ultraviolet (UV) light, may also contribute to retinal damage.

Diagnosis of wet AMD involves a comprehensive eye examination, including visual acuity tests and dilation to assess the retina. Optical coherence tomography (OCT) is commonly used to provide detailed cross-sectional images of the retina, highlighting fluid accumulation or swelling. Fluorescein angiography may also be performed, where a dye is injected into the bloodstream to map abnormal blood vessels in the retina.

The primary treatment for wet AMD is intravitreal injection of anti-VEGF medications, such as ranibizumab, aflibercept, or bevacizumab, which block the growth of abnormal blood vessels and reduce fluid leakage. Regular injections are often required to maintain vision. Photodynamic therapy (PDT) with verteporfin is another option, particularly for patients who cannot tolerate anti-VEGF treatment. In advanced cases, low-vision aids and rehabilitation may help patients adapt to vision loss. Lifestyle modifications, such as smoking cessation, maintaining a healthy diet rich in leafy greens and omega-3 fatty acids, and managing cardiovascular risk factors, are crucial in managing disease progression.

""Wet Age-Related Macular Degeneration (Wet-AMD)- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Wet Age-Related Macular Degeneration (Wet-AMD) pipeline landscape is provided which includes the disease overview and Wet Age-Related Macular Degeneration (Wet-AMD) treatment guidelines. The assessment part of the report embraces, in depth Wet Age-Related Macular Degeneration (Wet-AMD) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Wet Age-Related Macular Degeneration (Wet-AMD) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Wet Age-Related Macular Degeneration (Wet-AMD) R&D. The therapies under development are focused on novel approaches to treat/improve Wet Age-Related Macular Degeneration (Wet-AMD).

Wet Age-Related Macular Degeneration (Wet-AMD) Emerging Drugs Chapters

This segment of the Wet Age-Related Macular Degeneration (Wet-AMD) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, II/III I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Wet Age-Related Macular Degeneration (Wet-AMD) Emerging Drugs

• ONS-5010: Outlook Therapeutics

ONS-5010 / LYTENAVA™ (bevacizumab-vikg) is an investigational ophthalmic formulation of bevacizumab under development to be administered as an intravitreal injection for the treatment of wet AMD and other approved retinal diseases. Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. Following intravitreal injection the binding of bevacizumab-vikg to VEGF prevents the interaction of VEGF with its receptors on the surface of endothelial cells, reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation in the retina. Currently the drug is been registered for the treatment of Wet Age-Related Macular Degeneration (Wet-AMD).

• OPT-302: Opthea

OPT-302 is a soluble form of vascular endothelial growth factor receptor (VEGFR)-3 expressed as an immunoglobulin G1 (IgG1) Fc-fusion protein. It binds and neutralizes the activity of vascular endothelial growth factor (VEGF)-C and VEGF-D on their endogenous receptors, VEGFR-2 and VEGFR-3. Targeted inhibition of VEGF-C and VEGF-D can prevent blood vessel growth and vascular leakage, which contribute to the pathophysiology of retinal diseases including neovascular “wet” AMD. It is a first-in-class intravitreally administered biologic “trap” inhibitor of vascular endothelial growth factors C (VEGF-C) and D (VEGF-D) currently being investigated in two concurrent Phase III pivotal registrational trials that will each enroll ~990 treatment naïve patients, in combination with two approved anti-VEGF-A treatments, ranibizumab (ShORe trial) and aflibercept (COAST trial). OPT-302 has the potential to be positioned as complementary and agnostic with any combined anti–VEGF-A therapy for the treatment of wet AMD, a strategy intended to maximize the commercial opportunity for the therapy. Currently the drug in in Phase III stage of its treatment of Wet Age-Related Macular Degeneration (Wet-AMD).

• SYL1801: Sylentis

SYL1801 is a small interfering RNA (siRNA) in the non-clinical research phase. This siRNA, by means of mechanism of action based on RNA interference (RNAi), inhibits the synthesis of NRARP (Notch-regulated ankyrin repeat-containing protein). NRARP is directly involved in the pathophysiology of choroidal neovascularization, i.e. the abnormal formation of new vessels from the choroid into the retina. It is a common hallmark of several retinal diseases such as age-related macular degeneration (AMD) or diabetic retinopathy (DR). During angiogenesis (new vessel formation), NRARP integrates the Notch and Wnt signaling pathways by controlling stalk cell proliferation to stabilize new endothelial cell connections . Currently the drug in in Phase II stage of its treatment of Wet Age-Related Macular Degeneration (Wet-AMD).

• BI 836880: Boehringer Ingelheim

BI 836880 is a humanized bispecific nanobody comprising blocking domains for VEGF and angiopoietin-2 (Ang2). BI 836880 is a potent and selective inhibitor of VEGF and Ang2. By binding to VEGF and Ang2, BI 836880 inhibits tumor angiogenesis and vascularization and enhances the tumor microenvironment to support T-cell trafficking and function in the tumor. BI 836880 is currently being investigated in Phase II clinical studies for solid tumors and in Phase I/II clinical studies to treat wet AMD and non-small cell lung cancer.

Further product details are provided in the report……..

Wet Age-Related Macular Degeneration (Wet-AMD): Therapeutic Assessment

This segment of the report provides insights about the different Wet Age-Related Macular Degeneration (Wet-AMD) drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Wet Age-Related Macular Degeneration (Wet-AMD)

There are approx. 60+ key companies which are developing the therapies for Wet Age-Related Macular Degeneration (Wet-AMD). The companies which have their Wet Age-Related Macular Degeneration (Wet-AMD) drug candidates in the most advanced stage, i.e. Phase III include, Outlook Therapeutics.

• Phases

DelveInsight’s report covers around 70+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Wet Age-Related Macular Degeneration (Wet-AMD) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Wet Age-Related Macular Degeneration (Wet-AMD): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Wet Age-Related Macular Degeneration (Wet-AMD) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Wet Age-Related Macular Degeneration (Wet-AMD) drugs.

Wet Age-Related Macular Degeneration (Wet-AMD) Report Insights

• Wet Age-Related Macular Degeneration (Wet-AMD) Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Wet Age-Related Macular Degeneration (Wet-AMD) Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Wet Age-Related Macular Degeneration (Wet-AMD) drugs?
• How many Wet Age-Related Macular Degeneration (Wet-AMD) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Wet Age-Related Macular Degeneration (Wet-AMD)?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Wet Age-Related Macular Degeneration (Wet-AMD) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Wet Age-Related Macular Degeneration (Wet-AMD) and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Outlook Therapeutics
• Opthea
• Sylentis
• Boehringer Ingelheim
• Molecular Partners
• Sam Chun Dang Pharm
• Generium
• Alvotech
• Adverum Biotechnologies
• EyePoint Pharmaceuticals
• 4D Molecular Therapeutics
• OliX Pharmaceuticals
• Kyowa Kirin
• Exonate

Key Products

• ONS-5010
• OPT-302
• SYL1801
• BI 836880
• Abicipar pegol
• SCD411
• GNR-067
• AVT06
• ADVM-022
• EYP-1901
• 4D-150
• OLX10212
• KHK4951
• EXN 169

Please Note: It will take 3-4 business days to complete the report upon order confirmation. Show more